NASDAQ:CABA Cabaletta Bio (CABA) Stock Price, News & Analysis → Nvidia’s Quiet $1 Trillion Pivot (From Weiss Ratings) (Ad) Free CABA Stock Alerts $10.67 -0.25 (-2.29%) (As of 05/28/2024 ET) Add Compare Share Share Today's Range$10.53▼$11.2050-Day Range$10.48▼$18.8252-Week Range$9.02▼$26.35Volume631,612 shsAverage Volume1.03 million shsMarket Capitalization$515.15 millionP/E RatioN/ADividend YieldN/APrice Target$34.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Cabaletta Bio alerts: Email Address Cabaletta Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside225.7% Upside$34.33 Price TargetShort InterestHealthy18.85% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.01Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.07) to ($2.39) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.07 out of 5 starsMedical Sector869th out of 931 stocksBiological Products, Except Diagnostic Industry150th out of 154 stocks 3.5 Analyst's Opinion Consensus RatingCabaletta Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCabaletta Bio has only been the subject of 4 research reports in the past 90 days.Read more about Cabaletta Bio's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted18.85% of the outstanding shares of Cabaletta Bio have been sold short.Short Interest Ratio / Days to CoverCabaletta Bio has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Cabaletta Bio has recently decreased by 11.22%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCabaletta Bio does not currently pay a dividend.Dividend GrowthCabaletta Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CABA. Previous Next 1.7 News and Social Media Coverage News SentimentCabaletta Bio has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Cabaletta Bio this week, compared to 3 articles on an average week.Search InterestOnly 15 people have searched for CABA on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.MarketBeat Follows4 people have added Cabaletta Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cabaletta Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.88% of the stock of Cabaletta Bio is held by insiders.Read more about Cabaletta Bio's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Cabaletta Bio are expected to decrease in the coming year, from ($2.07) to ($2.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cabaletta Bio is -6.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cabaletta Bio is -6.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCabaletta Bio has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cabaletta Bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. About Cabaletta Bio Stock (NASDAQ:CABA)Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Read More CABA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CABA Stock News HeadlinesMay 25 at 9:47 AM | americanbankingnews.comCabaletta Bio (NASDAQ:CABA) Receives "Buy" Rating from HC WainwrightMay 20, 2024 | americanbankingnews.comBrokers Offer Predictions for Cabaletta Bio, Inc.'s FY2024 Earnings (NASDAQ:CABA)May 20, 2024 | americanbankingnews.comCabaletta Bio, Inc. (NASDAQ:CABA) to Post Q2 2024 Earnings of ($0.58) Per Share, William Blair ForecastsMay 20, 2024 | americanbankingnews.comCabaletta Bio, Inc. (NASDAQ:CABA) to Post Q2 2024 Earnings of ($0.47) Per Share, HC Wainwright ForecastsMay 19, 2024 | americanbankingnews.comEquities Analysts Set Expectations for Cabaletta Bio, Inc.'s FY2028 Earnings (NASDAQ:CABA)May 18, 2024 | americanbankingnews.comCabaletta Bio (NASDAQ:CABA) Stock Rating Reaffirmed by HC WainwrightMay 16, 2024 | msn.comCabaletta Bio Reports Promising Advances in Autoimmune Disease Trials, Looks to Future InnovationsMay 15, 2024 | markets.businessinsider.comWilliam Blair Reaffirms Their Buy Rating on Cabaletta Bio (CABA)May 15, 2024 | investorplace.comCABA Stock Earnings: Cabaletta Bio Misses EPS for Q1 2024May 15, 2024 | finance.yahoo.comCabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 15, 2024 | globenewswire.comCabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 15, 2024 | msn.comCabaletta Bio to Present at H.C. Wainwright BioConnect Investor ConferenceMay 13, 2024 | globenewswire.comCabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQMay 10, 2024 | msn.comRetinopathy With Long-Term HCQ Use: Large Study IDs Risk FactorsMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cabaletta Bio as CABA-201 Enters RESET Trial with Promising Therapeutic PotentialApril 27, 2024 | investing.comCabaletta Bio Inc (CABA)April 18, 2024 | msn.comPhilly-area biotech is worried about Congress’ crackdown on Chinese manufacturersApril 17, 2024 | msn.com🛠️ One Philly rowhouse at a time | Morning NewsletterMarch 23, 2024 | investing.comStifel lifts Cabaletta Bio target to $32 on myositis positionMarch 23, 2024 | finance.yahoo.comCabaletta Bio Inc (CABA) Earnings: Aligns with EPS Projections, Forecasts Extended Cash RunwayMarch 22, 2024 | markets.businessinsider.comStrong Buy on Cabaletta Bio: Promising CAR T Candidate and Robust Financial OutlookMarch 21, 2024 | markets.businessinsider.comCabaletta Bio Earns ‘Buy’ Rating on Impressive Clinical Progress and Strategic Market PositioningMarch 21, 2024 | investorplace.comCABA Stock Earnings: Cabaletta Bio Misses EPS for Q4 2023March 21, 2024 | msn.comCabaletta gets FDA orphan drug status for systemic sclerosis drugMarch 21, 2024 | finance.yahoo.comCabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateSee More Headlines Receive CABA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cabaletta Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today5/28/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CABA CUSIPN/A CIK1759138 Webwww.cabalettabio.com Phone267-759-3100FaxN/AEmployees118Year FoundedN/APrice Target and Rating Average Stock Price Target$34.33 High Stock Price Target$50.00 Low Stock Price Target$25.00 Potential Upside/Downside+225.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-67,680,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-38.77% Return on Assets-36.09% Debt Debt-to-Equity RatioN/A Current Ratio12.66 Quick Ratio12.66 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.51 per share Price / Book1.91Miscellaneous Outstanding Shares48,280,000Free Float43,507,000Market Cap$508.87 million OptionableOptionable Beta2.52 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Steven A. Nichtberger M.D. (Age 63)Co-Founder, Chairman, CEO & President Comp: $1.02MDr. Gwendolyn K. Binder Ph.D. (Age 49)President of Science & Technology Comp: $722.62kDr. David J. Chang FACR (Age 61)M.D., M.P.H., Chief Medical Officer Comp: $721.85kDr. Michael C. Milone M.D.Ph.D., Co-Founder & Co-Chair of Scientific Advisory BoardDr. Aimee Payne M.D.Ph.D., Co-Founder & Co-Chair of Scientific Advisory BoardMr. Anup Marda M.B.A. (Age 46)Chief Financial Officer Comp: $548.2kDr. Samik Basu M.D.Chief Scientific OfficerMr. Michael Gerard J.D. (Age 44)General Counsel & Secretary Ms. Heather Harte-Hall M.Sc.Chief Compliance OfficerMs. Martha O'ConnorChief Human Resources OfficerMore ExecutivesKey CompetitorsKyverna TherapeuticsNASDAQ:KYTXValnevaNASDAQ:VALNExscientiaNASDAQ:EXAITaysha Gene TherapiesNASDAQ:TSHAiTeos TherapeuticsNASDAQ:ITOSView All CompetitorsInsiders & InstitutionsTeachers Retirement System of The State of KentuckyBought 17,905 shares on 5/28/2024Ownership: 0.037%Bain Capital Life Sciences Investors LLCSold 382,636 shares on 5/16/2024Ownership: 3.456%Blackstone Inc.Sold 300,714 shares on 5/16/2024Ownership: 0.100%California State Teachers Retirement SystemBought 1,711 shares on 5/16/2024Ownership: 0.065%Bayesian Capital Management LPBought 11,187 shares on 5/16/2024Ownership: 0.024%View All Insider TransactionsView All Institutional Transactions CABA Stock Analysis - Frequently Asked Questions Should I buy or sell Cabaletta Bio stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cabaletta Bio in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CABA shares. View CABA analyst ratings or view top-rated stocks. What is Cabaletta Bio's stock price target for 2024? 9 Wall Street analysts have issued twelve-month price objectives for Cabaletta Bio's stock. Their CABA share price targets range from $25.00 to $50.00. On average, they predict the company's stock price to reach $34.33 in the next year. This suggests a possible upside of 225.7% from the stock's current price. View analysts price targets for CABA or view top-rated stocks among Wall Street analysts. How have CABA shares performed in 2024? Cabaletta Bio's stock was trading at $22.70 at the beginning of the year. Since then, CABA shares have decreased by 53.6% and is now trading at $10.54. View the best growth stocks for 2024 here. Are investors shorting Cabaletta Bio? Cabaletta Bio saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 9,100,000 shares, a decrease of 11.2% from the April 30th total of 10,250,000 shares. Based on an average trading volume of 1,130,000 shares, the days-to-cover ratio is currently 8.1 days. View Cabaletta Bio's Short Interest. When is Cabaletta Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our CABA earnings forecast. How were Cabaletta Bio's earnings last quarter? Cabaletta Bio, Inc. (NASDAQ:CABA) announced its earnings results on Thursday, March, 21st. The company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by $0.07. What ETFs hold Cabaletta Bio's stock? ETFs with the largest weight of Cabaletta Bio (NASDAQ:CABA) stock in their portfolio include Alger Mid Cap 40 ETF (FRTY).Alger 35 ETF (ATFV). What other stocks do shareholders of Cabaletta Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cabaletta Bio investors own include Alector (ALEC), Editas Medicine (EDIT), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Homology Medicines (FIXX), Skyworks Solutions (SWKS), CrowdStrike (CRWD), Precision BioSciences (DTIL), Invitae (NVTA) and Pfizer (PFE). When did Cabaletta Bio IPO? Cabaletta Bio (CABA) raised $87 million in an initial public offering on Friday, October 25th 2019. The company issued 5,800,000 shares at $14.00-$16.00 per share. Morgan Stanley, Cowen and Company and Evercore Group acted as the underwriters for the IPO. Who are Cabaletta Bio's major shareholders? Cabaletta Bio's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Jennison Associates LLC (7.31%), Vanguard Group Inc. (4.86%), Bain Capital Life Sciences Investors LLC (3.46%), Price T Rowe Associates Inc. MD (1.31%), StemPoint Capital LP (0.00%) and Redmile Group LLC (0.95%). Insiders that own company stock include Anup Marda, Catherine Bollard, Gwendolyn Binder, Steven Nichtberger and Ventures V LP 5Am. View institutional ownership trends. How do I buy shares of Cabaletta Bio? Shares of CABA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CABA) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersWARNING about the death of the U.S. dollar…Colonial MetalsTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy SykesElon’s New Device is About to Shock the WorldInvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto for AIWeiss RatingsThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaDigitizing the $11T commodities sector with one tiny stockResource Stock Digest Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cabaletta Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.